WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a clinical stage biotechnology company spearheading the movement to harness the body’s innate regenerative potential with its Progenitor Cell ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics today announced that the first patients have been treated in a Phase 1/2 clinical trial to evaluate FX-322, a first-in-class drug candidate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback